A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...
Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Key Takeaways For Merck & Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE, EBITDA ...
Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...
BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...
This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback